Fazirsiran

3 trials 3 recruiting Orphan designation

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

3 Recruiting

0 Completed trials

1 Sponsors

13 Countries

Phase III

Phase III: 3

Indications tested

Alpha-1 anti-trypsin deficiency 2

Sponsors using this IMP

Takeda Development Center Americas Inc. 3

All trials

3 total

Study to learn about the safety of fazirsiran and if it can help people with alpha-1 antitrypsin liver disease with mild liver scarring (fib… Recruiting

2023-504198-19-00 Phase III 10 countries Takeda Development Center Americas Inc.
An Open-Label Extension Study of Fazirsiran Recruiting

2023-503497-21-00 Phase III 3 countries Takeda Development Center Americas Inc.
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnorma… Recruiting

2022-501943-34-00 Phase III 13 countries Takeda Development Center Americas Inc.

Showing 1–3 of 3 trials

← All drugs A–Z